trial · primary record
Venetoclax
Chronic Lymphocytic Leukemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2030-12-31 |
| Primary endpoint | The primary objective is to evaluate complete response (CR) rate, per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, 2018 |
| Registry ID | NCT06520098 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:04.789Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06520098
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Venetoclax · approval
- Venetoclax · compound